Demand for excipients to rise; TheraBiogen launches migraine nasal spray;

> In one measure of the increasing importance of drug delivery, the U.S. demand for excipients will rise 3.9 percent a year to $1.9 billion in 2015. Excipients can, among other things, control the release of medication. Story

> TheraBiogen has launched a nasal spray for migraine relief. Item

> Biogen Idec has obtained the European Commission's approval for its Avonex Pen for patients who are suffering from relapsing multiple sclerosis. Avonex Pen is a single-use, once-a-week, intramuscular autoinjector. The needle is hidden prior to injection. More here

> Helicon Group's electronic drug delivery device for syringes successful in tests. Article

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.